ML239

CAS No. 1378872-36-6

ML239( —— )

Catalog No. M17266 CAS No. 1378872-36-6

ML239 is a potent and selective inhibitor of breast cancer stem cells, with an IC50 of 1.16 μM.

Purity : >98% (HPLC)

COA Datasheet HNMR HPLC MSDS Handing Instructions
Size Price / USD Stock Quantity
5MG 39 In Stock
10MG 65 In Stock
25MG 129 In Stock
50MG 250 In Stock
100MG 429 In Stock
200MG Get Quote In Stock
500MG Get Quote In Stock
1G Get Quote In Stock

Biological Information

  • Product Name
    ML239
  • Note
    Research use only, not for human use.
  • Brief Description
    ML239 is a potent and selective inhibitor of breast cancer stem cells, with an IC50 of 1.16 μM.
  • Description
    ML239 is a potent and selective inhibitor of breast cancer stem cells, with an IC50 of 1.16 μM.
  • In Vitro
    ML239 (Compound 7j) is a potent and selective inhibitor of breast cancer stem cells, with an IC50 of 1.16 μM, with ~24-fold selectivity against the control cell line. ML239 inhibits breast cancer stem-like cells, most likely through activation of fatty acid desaturase 2 (FADS2). ML239 is cytotoxic to NCIH661 cells, and FADS2 knockdown reduces ML239 cytotoxicity, and furthermore, FADS2 inhibitor SC-26196 also reduces ML239 cytotoxicity in cancer cell lines (CCLs).
  • In Vivo
    ——
  • Synonyms
    ——
  • Pathway
    PI3K/Akt/mTOR signaling
  • Target
    mTOR
  • Recptor
    Others
  • Research Area
    Cancer
  • Indication
    ——

Chemical Information

  • CAS Number
    1378872-36-6
  • Formula Weight
    346.59
  • Molecular Formula
    C13H10Cl3N3O2
  • Purity
    >98% (HPLC)
  • Solubility
    DMSO : ≥ 300 mg/mL 865.55 mM
  • SMILES
    Clc2cc(Cl)cc(Cl)c2OCC(=O)N\N=C\c1cccn1
  • Chemical Name
    ——

Shipping & Storage Information

  • Storage
    (-20℃)
  • Shipping
    With Ice Pack
  • Stability
    ≥ 2 years

Reference

1.Germain AR,etal.Identification of a selective small molecule inhibitor of breast cancer stem cells.Bioorg Med Chem Lett. 2012 May 15;22(10):3571-4.
molnova catalog
related products
  • PRT-060318

    PRT-060318 (PRT318) is a novel selective inhibitor of the Syk tyrosine kinase, as an approach to HIT treatment.

  • Sapanisertib

    Sapanisertib (INK-128, MLN0128) is a potent, ATP-competitive, orally active dual mTORC1/2 inhibitor with Ki of 1.4 nM in cell-free assays.

  • Autogramin-1

    Autogramin-1 potently inhibits starvation-induced autophagy with IC50 of 0.17 μM.